Kumar L, Bhargava V L
Department of Medical Oncology and Gynaecology, All India Institute of Medical Sciences, New Delhi.
Gynecol Oncol. 1991 Feb;40(2):107-11. doi: 10.1016/0090-8258(91)90100-j.
Twenty-five patients, ranging from 21 to 61 years of age (median = 45 years), with histologically proven recurrent and advanced cervical cancer were treated with chemotherapy using a combination of bleomycin, ifosfamide, and cis-platinum (BIP). Twenty-one patients were evaluable for response. Ninety percent of patients achieved a subjective response. An objective response was noted in 14 of 21 (66.6%) patients: complete in 4 (19%) and partial in 10 (47.6%). Side effects were mainly nausea/vomiting, alopecia, myelosuppression, reversible encephalopathy, and impaired renal function. One patient died from the toxic effects of chemotherapy. These results indicate that BIP is an active combination in recurrent cervical cancer with acceptable toxicity.
25例年龄在21至61岁（中位数=45岁）之间、经组织学证实为复发性和晚期宫颈癌的患者接受了博来霉素、异环磷酰胺和顺铂联合化疗（BIP）。21例患者可评估疗效。90%的患者获得主观缓解。21例患者中有14例（66.6%）出现客观缓解：4例（19%）完全缓解，10例（47.6%）部分缓解。副作用主要为恶心/呕吐、脱发、骨髓抑制、可逆性脑病和肾功能损害。1例患者死于化疗毒性作用。这些结果表明，BIP是复发性宫颈癌的一种有效的联合化疗方案，且毒性可接受。
